TJ191 |
Catalog No.GC62676 |
Le TJ191 est un agent anticancéreux puissant et spécifique qui cible les cellules malignes de leucémie/lymphome T malins exprimant TβRIII. TJ191 n'a aucun effet sur la prolifération d'autres cellules cancéreuses ou de fibroblastes normaux ou de cellules immunitaires. TJ191 peut être utilisé pour la recherche sur le cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1522415-97-9
Sample solution is provided at 25 µL, 10mM.
TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research[1].
TJ191(0-100 µM; 24 hours) exhibits pronounced anti-proliferative activity in malignant cell lines, the IC50 values are 0.13 µM, 0.13±0.08 µM, 0.26±0.19 µM, 0.22±0.11 µM, 1.5±0.02 µM, 0.32±0.086 µM, 3.1±0.5 µM, 0.26±0.16 µM in CEM, JURKAT, MOLT-3, MOLT-4, SUP-T1, MT-2, C8166 and HSB-2 cells, respectively. But has no effects in HUT-78 (IC50=17±10 µM) and MT-4 (IC50=47 ± 5 µM) cells[1].TJ191 (0.1-3 µM; 8 or 24 hours) induces CEM cell apoptosis in a concentration- and time-dependent manner. Even at 0.3 µM, TJ191 induces the maximum apoptotic rate of 80% after 24 h[1].
[1]. Ahmed El-Gazzar, et al. 2-Amino-3-methylcarboxy-5-heptyl-thiophene (TJ191) is a selective anti-cancer small molecule that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. Oncotarget. 2017 Dec 15;9(5):6259-6269.
Average Rating: 5
(Based on Reviews and 28 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *